The Small Animal Imaging Facility (SAIF) provides Cancer Center Members with powerful imaging technologies, staff and expertise necessary to integrate imaging into preclinical cancer research. The facility is led by Drs. John D. Hazle and James A. Bankson and is supported by a network of faculty with research expertise in each imaging modality. Faculty and staff consult with users prior to planning of imaging experiments, and assist in all aspects of imaging services, including preparation of grants, experimental design, protocol optimization, data acquisition and analysis, interpretation, presentation, and publication of results. Instrumentation and full-service support are available for preclinical MRI (4.7T/40cm, 7.0T/30cm) including hyperpolarized """"""""C-labeled tracers (such as [1-^^C]-pyruvate), x-ray computed tomography (in-vivo and specimen), micro-ultrasound, digital planar x-ray, nuclear imaging using PET, SPECT, and gamma camera, and optical (bioluminescence/fluorescence) imaging. More than $2.5M of institutional support allowed for upgrade, expansion, or addition of significant new services in ultrasound, optical, and MR imaging, hyperpolarized tracers, and image-guided radiation therapy. A modest 6.3% growth in overall utilization by hours during this period belies a continually expanding base of users supported by federal funding. 118 distinct principal investigators affiliated with 19 CCSG Programs made use of SAIF resources during this funding period. Peer-reviewed investigators account for 89% of the utilization, and 24% of the total costs are requested from the CCSG. Overall, the number of federally funded investigators making use of SAIF resources grew by more than 275% compared to the prior period. The requested CCSG support for these services corresponds to 24% of the projected operating budget. Publications cited using the SAIF have appeared in Proc Natl Acad Sci and J Natl Cancer Inst. In the forthcoming period, new satellite facilities in the South Campus Vivarium and the Center for Advanced Biomedical Imaging Research will be added, and new services will be offered in image-guided radiation therapy and metabolic imaging using hyperpolarized tracers.

Public Health Relevance

The Small Animal Imaging Facility provides access to imaging instrumentation and expertise that allows Cancer Center Members to integrate powerful and cutting-edge imaging technologies into routine preclinical research with confidence that their scientific objectives will be achieved. The SAIF has also developed a new multi-animal imaging platform to reduce the cost of imaging in small animal research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759773
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$235,740
Indirect Cost
$88,465
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications